Alex Eccleston's profile photo

Alex Eccleston

Senior Editor, Biology at Nature

Featured in: Favicon nature.com

Articles

  • 4 weeks ago | nature.com | Alex Eccleston

    RESEARCH HIGHLIGHT 09 May 2025 Ubiquitylation is a vital post-translation modification that controls protein stability, activity and localization and is disrupted in many diseases. Around 650 E3 ubiquitin ligases each recognize a specific set of substrates and are potentially attractive therapeutic targets, but they often lack a confined active-site pocket amenable to small-molecule inhibition. Reporting in Cell, Rothman et al.

  • 2 months ago | nature.com | Alex Eccleston

    RESEARCH HIGHLIGHT 24 March 2025 Non-opioid therapeutics for chronic pain are urgently required, given that opioids lead to dangerous side effects, addiction and tolerance. Agonists of the type 1 cannabinoid receptor (CB1) show promise as alternative analgesics but are still limited by side effects and tolerance. Reporting in Nature, Rangari et al.

  • Feb 26, 2025 | nature.com | Alex Eccleston

    RESEARCH HIGHLIGHT 26 February 2025 Molecular glue degraders are small molecules that promote the interaction of a target protein with an E3 ubiquitin ligase to induce proteasome-mediated degradation. Most glue degraders have been discovered serendipitously, and the paucity of well characterized examples limits their rational discovery as therapeutics.

  • Feb 5, 2025 | nature.com | Alex Eccleston

    RESEARCH HIGHLIGHT 05 February 2025 Subcellular assemblies of proteins and nucleic acids termed biomolecular condensates can form by phase separation to compartmentalize biochemical reactions and other processes. Reporting in Nature, Xie et al. show that phase separation of the FOXM1 transcription factor is important for its oncogenic function and is inhibited by AMP-activated protein kinase (AMPK) phosphorylation.

  • Jan 7, 2025 | nature.com | Alex Eccleston

    RESEARCH HIGHLIGHT 07 January 2025 Ionizable lipid nanoparticles (LNPs) that deliver nucleic acid therapeutics to the liver have been successful in the clinic, but achieving LNP delivery to other organs has been challenging. Reporting in Nature, Swingle et al. use a DNA barcoding approach to identify an LNP formulation that delivers therapeutic mRNA to the placenta and alleviates hypertension in mouse models of pre-eclampsia.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →